-
Something wrong with this record ?
The Impact of COVID-19 Third Dose Vaccination on the Magnitude of Antigen Specific T Cells in Kidney Transplant Patients
E. Girmanova, J. Duskova, P. Mrazova, M. Fialova, O. Viklicky, P. Hruba
Status minimal Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- COVID-19 * immunology prevention & control MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Antibodies, Viral blood MeSH
- SARS-CoV-2 immunology MeSH
- Aged MeSH
- T-Lymphocytes * immunology MeSH
- Kidney Transplantation * adverse effects MeSH
- Vaccination methods MeSH
- COVID-19 Vaccines * immunology administration & dosage MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Measuring T cell response can add information about antivirus immunity provided by antibody test results. The study evaluates the impact of a third mRNA COVID-19 vaccine dose on T cell response and antibody production in kidney transplant recipients (25 KTRs) versus healthy controls (26 Hc). Results show a significant rise in S-activated CD4+CD154+IFN?+TNF?+ double producer cells in both KTRs (p=0.025) and Hc (p=0.009) as well as increased spike antibody response in KTRs (p=0.00019) and Hc (p=3.10-8) third-month post-third dose. Moreover, the study revealed a drop in seronegative KTRs (non-responders) from 9/25 (36%) pre-third dose to 2/25 (7%) at 3 months post-third dose while 5/9 (56%) of non-responders post-second dose showed specific T cell responses. Notably, the third dose significantly improved seroconversion rates in both KTRs and Hc, although Hc individuals exhibited higher antibody levels. Key words: mRNA COVID-19 vaccine, T cells, SARS-CoV-2 antibodies, Kidney transplantation, mRNA vaccination.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017599
- 003
- CZ-PrNML
- 005
- 20250312151318.0
- 007
- ta
- 008
- 241004s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935318 $2 doi
- 035 __
- $a (PubMed)39264085
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Girmanova, E $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. petra.hruba@ikem.cz
- 245 14
- $a The Impact of COVID-19 Third Dose Vaccination on the Magnitude of Antigen Specific T Cells in Kidney Transplant Patients / $c E. Girmanova, J. Duskova, P. Mrazova, M. Fialova, O. Viklicky, P. Hruba
- 520 9_
- $a Measuring T cell response can add information about antivirus immunity provided by antibody test results. The study evaluates the impact of a third mRNA COVID-19 vaccine dose on T cell response and antibody production in kidney transplant recipients (25 KTRs) versus healthy controls (26 Hc). Results show a significant rise in S-activated CD4+CD154+IFN?+TNF?+ double producer cells in both KTRs (p=0.025) and Hc (p=0.009) as well as increased spike antibody response in KTRs (p=0.00019) and Hc (p=3.10-8) third-month post-third dose. Moreover, the study revealed a drop in seronegative KTRs (non-responders) from 9/25 (36%) pre-third dose to 2/25 (7%) at 3 months post-third dose while 5/9 (56%) of non-responders post-second dose showed specific T cell responses. Notably, the third dose significantly improved seroconversion rates in both KTRs and Hc, although Hc individuals exhibited higher antibody levels. Key words: mRNA COVID-19 vaccine, T cells, SARS-CoV-2 antibodies, Kidney transplantation, mRNA vaccination.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 650 12
- $a COVID-19 $x imunologie $x prevence a kontrola $7 D000086382
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a vakcíny proti COVID-19 $x imunologie $x aplikace a dávkování $7 D000086663
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a T-lymfocyty $x imunologie $7 D013601
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a SARS-CoV-2 $x imunologie $7 D000086402
- 650 _2
- $a vakcinace $x metody $7 D014611
- 650 _2
- $a senioři $7 D000368
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Duskova, J
- 700 1_
- $a Mrazova, P
- 700 1_
- $a Fialova, M
- 700 1_
- $a Viklicky, O
- 700 1_
- $a Hruba, P
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, č. 4 (2024), s. 655-664
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39264085 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y - $z 0
- 990 __
- $a 20241004 $b ABA008
- 991 __
- $a 20250312151325 $b ABA008
- 999 __
- $a min $b bmc $g 2283511 $s 1229549
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c 4 $d 655-664 $e 20240831 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $a Pubmed-20241004
